Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bridgebio Pharma Inc
(NQ:
BBIO
)
24.74
-0.21 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,298,720
Open
24.88
Bid (Size)
24.75 (1)
Ask (Size)
24.89 (1)
Prev. Close
24.95
Today's Range
24.27 - 25.36
52wk Range
13.00 - 44.32
Shares Outstanding
160,500,999
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
April 07, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Performance
YTD
-38.84%
-38.84%
1 Month
-12.98%
-12.98%
3 Month
-34.13%
-34.13%
6 Month
+0.24%
+0.24%
1 Year
+48.32%
+48.32%
More News
Read More
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Recap: BridgeBio Pharma Q4 Earnings
February 22, 2024
Via
Benzinga
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 1/9
January 09, 2024
Via
Investor Brand Network
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
March 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
March 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
What's Going On With BridgeBio Pharma Stock On Monday?
March 04, 2024
Via
Benzinga
Exposures
Product Safety
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
March 04, 2024
Via
Investor's Business Daily
2 Biotechs That Could Get Bought Out in 2024
January 03, 2024
Via
The Motley Fool
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
March 04, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
February 22, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
February 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
February 07, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
February 05, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
February 02, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
3 Groundbreaking Biotech Stocks to Invest in Now
January 29, 2024
Via
InvestorPlace
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
January 22, 2024
Via
InvestorPlace
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
January 18, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
January 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
January 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
January 03, 2024
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed
December 18, 2023
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.